<DOC>
	<DOCNO>NCT00876044</DOCNO>
	<brief_summary>The primary objective study evaluate effect aflibercept QTc interval cancer patient . Secondary objective evaluate effect aflibercept electrocardiogram ( ECG ) parameter , clinical safety pharmakokinetic ( PK ) parameter .</brief_summary>
	<brief_title>A Study Evaluate Effects Aflibercept QTc Interval Cancer Patients</brief_title>
	<detailed_description>All patient receive background treatment docetaxel .</detailed_description>
	<criteria>Inclusion criterion : Solid malignancy , document pathologic report , treatment singleagent docetaxel ( administer every 3 week , dose &lt; 75 mg/m2 ) plan . Written inform consent Exclusion criterion : Patient receive 2 prior line cytotoxiccontaining chemotherapy Conditions screen ECG repolarization difficult interpret , show significant abnormality . This include , limited : high degree AV block , pacemaker , atrial fibrillation flutter QTcF &gt; 480 msec screen ECG The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>